| Literature DB >> 27667586 |
Manfred Weidmann1, Tatjana Avsic-Zupanc2, Silvia Bino3, Michelle Bouloy4, Felicity Burt5, Sadegh Chinikar6, Iva Christova7, Isuf Dedushaj8, Ahmed El-Sanousi9, Nazif Elaldi10, Roger Hewson11, Frank T Hufert12, Isme Humolli8, Petrus Jansen van Vuren13, Zeliha Koçak Tufan14, Gülay Korukluoglu15, Pieter Lyssen16, Ali Mirazimi17, Johan Neyts16, Matthias Niedrig18, Aykut Ozkul19, Anna Papa20, Janusz Paweska13, Amadou A Sall21, Connie S Schmaljohn22, Robert Swanepoel23, Yavuz Uyar24, Friedemann Weber25, Herve Zeller26.
Abstract
In countries from which Crimean-Congo haemorrhagic fever (CCHF) is absent, the causative virus, CCHF virus (CCHFV), is classified as a hazard group 4 agent and handled in containment level (CL)-4. In contrast, most endemic countries out of necessity have had to perform diagnostic tests under biosafety level (BSL)-2 or -3 conditions. In particular, Turkey and several of the Balkan countries have safely processed more than 100 000 samples over many years in BSL-2 laboratories. It is therefore advocated that biosafety requirements for CCHF diagnostic procedures should be revised, to allow the tests required to be performed under enhanced BSL-2 conditions with appropriate biosafety laboratory equipment and personal protective equipment used according to standardized protocols in the countries affected. Downgrading of CCHFV research work from CL-4, BSL-4 to CL-3, BSL-3 should also be considered.Entities:
Mesh:
Year: 2016 PMID: 27667586 DOI: 10.1099/jgv.0.000610
Source DB: PubMed Journal: J Gen Virol ISSN: 0022-1317 Impact factor: 3.891